BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33401328)

  • 1. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.
    Hariyanto TI; Hardyson W; Kurniawan A
    Drug Res (Stuttg); 2021 May; 71(5):265-274. PubMed ID: 33401328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection.
    Ivan Hariyanto T; Kurniawan A
    J Med Virol; 2021 Mar; 93(3):1832-1836. PubMed ID: 33241872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
    Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P;
    BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
    Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
    Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
    Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
    Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
    Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
    Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.
    Toda M; Fujii K; Yoshifuji A; Kondo Y; Itoh K; Sekine K; Kikuchi T; Ryuzaki M
    Clin Exp Nephrol; 2022 Jan; 26(1):75-85. PubMed ID: 34436742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis.
    Moosazadeh M; Mousavi T
    J Med Virol; 2022 Apr; 94(4):1350-1356. PubMed ID: 34850411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
    Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
    J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
    Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
    Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
    Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
    Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis.
    Zhang J; Chen C; Yang Y; Yang J
    Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Hariyanto TI; Halim DA; Jodhinata C; Yanto TA; Kurniawan A
    Clin Exp Pharmacol Physiol; 2021 Jun; 48(6):823-830. PubMed ID: 33719081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.